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IMPORTANCE Preventive interventions are needed to protect residents and staff of skilled
nursing and assisted living facilities from COVID-19 during outbreaks in their facilities.
Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid
protection from SARS-CoV-2 infection and COVID-19.
OBJECTIVE To determine the effect of bamlanivimab on the incidence of COVID-19 among
residents and staff of skilled nursing and assisted living facilities.
DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, single-dose, phase 3 trial
that enrolled residents and staff of 74 skilled nursing and assisted living facilities in the United
States with at least 1 confirmed SARS-CoV-2 index case. A total of 1175 participants enrolled in
the study from August 2 to November 20, 2020. Database lock was triggered on January 13,
2021, when all participants reached study day 57.
INTERVENTIONS Participants were randomized to receive a single intravenous infusion of
bamlanivimab, 4200 mg (n = 588), or placebo (n = 587).
MAIN OUTCOMES AND MEASURES The primary outcome was incidence of COVID-19, defined as
the detection of SARS-CoV-2 by reverse transcriptase–polymerase chain reaction and mild or
worse disease severity within 21 days of detection, within 8 weeks of randomization. Key
secondary outcomes included incidence of moderate or worse COVID-19 severity and
incidence of SARS-CoV-2 infection.
RESULTS The prevention population comprised a total of 966 participants (666 staff and 300
residents) who were negative at baseline for SARS-CoV-2 infection and serology (mean age,
53.0 [range, 18-104] years; 722 [74.7%] women). Bamlanivimab significantly reduced the
incidence of COVID-19 in the prevention population compared with placebo (8.5% vs 15.2%;
odds ratio, 0.43 [95% CI, 0.28-0.68]; P < .001; absolute risk difference, −6.6 [95% CI, −10.7
to −2.6] percentage points). Five deaths attributed to COVID-19 were reported by day 57; all
occurred in the placebo group. Among 1175 participants who received study product (safety
population), the rate of participants with adverse events was 20.1% in the bamlanivimab
group and 18.9% in the placebo group. The most common adverse events were urinary tract
infection (reported by 12 participants [2%] who received bamlanivimab and 14 [2.4%] who
received placebo) and hypertension (reported by 7 participants [1.2%] who received
bamlanivimab and 10 [1.7%] who received placebo).
CONCLUSIONS AND RELEVANCE Among residents and staff in skilled nursing and assisted living
facilities, treatment during August-November 2020 with bamlanivimab monotherapy
reduced the incidence of COVID-19 infection. Further research is needed to assess preventive
efficacy with current patterns of viral strains with combination monoclonal antibody therapy.
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S ARS-CoV-2 continues to spread globally, resulting in as-sociated morbidity, increased mortality, and overallstrain on health care resources. Outbreaks of COVID-19
within nursing homes and assisted living facilities have been
associated with high rates of morbidity and mortality.1-3 In the
United States, as of February 2021, long-term care facilities ac-
counted for 5% of reported COVID-19 cases but a dispropor-
tionate 37% of deaths.4 Residents have an increased risk of de-
velopment of severe COVID-19 and associated mortality as they
are generally older and have multiple comorbidities.5-8 Close
living environments, presymptomatic and asymptomatic trans-
mission of SARS-CoV-2,1,9,10 and frequent staff contact re-
quired to meet the care needs of frail residents have contrib-
uted to SARS-CoV-2 transmission.
While the emergence of efficacious vaccines is a critical
step in addressing the COVID-19 pandemic, other preventive
interventions, such as passive immunization, may protect
vulnerable populations until widespread immunization is
achieved. Additionally, vaccines may have decreased efficacy
or durability in such populations.11 Neutralizing monoclonal
antibodies that recognize the spike protein of SARS-CoV-2
may provide protection against COVID-19 or SARS-CoV-2
infection.12 Bamlanivimab, alone or in combination with ete-
sevimab, received an Emergency Use Authorization for the
treatment of mild to moderate COVID-19 in individuals at
high risk of severe COVID-1913,14 based on data from an ongo-
ing phase 2/3 study (NCT04427501). Treatment with
bamlanivimab reduced nasopharyngeal viral load and COVID-
19–related hospitalizations or emergency department visits
compared with placebo.15
Preclinical studies have provided support for the prem-
ise that bamlanivimab may be a viable clinical prophylactic in-
tervention, as demonstrated by reduced viral replication and
load in the upper and lower airways in rhesus macaques in
SARS-CoV-2 challenge studies.12 The phase 3 BLAZE-2 trial was
designed to evaluate the efficacy of bamlanivimab in prevent-
ing COVID-19 in skilled nursing and assisted living facility resi-
dents and staff.
North Carolina, Ohio, Pennsylvania, and Virginia). All 74 fa-
cilities had at least 1 confirmed SARS-CoV-2 index case.
The original and final protocols for the phase 3 trial, includ-
ing the original and final statistical analysis plans, appear in
Supplement 1.
Within 7 days of a reported confirmed SARS-CoV-2 case
at a facility, residents and staff of the facility were screened
for enrollment, and, if eligible, randomly assigned and dosed
with 4200 mg of intravenous bamlanivimab or placebo
(saline). All participants were aged 18 years or older and
had no known history of COVID-19. Participants provided
both nasal and nasopharyngeal swabs (baseline samples)
for detection of SARS-CoV-2 by reverse transcriptase–
polymerase chain reaction (RT-PCR) and blood samples for
SARS-CoV-2 serology tests. Serum was tested for anti–SARS-
CoV-2 antibodies using the Elecsys anti–SARS-CoV-2 electro-
chemiluminescence immunoassay intended for qualitative
detection of antibodies to SARS-CoV-2 on a cobas e 602
(Roche Diagnostics). Additional information about the meth-
ods used to detect SARS-CoV-2 by RT-PCR and to test for
anti-SARS-CoV-2 antibodies is available in the eAppendix in
Supplement 2. Participants were randomized and received
the trial product (bamlanivimab or placebo) before the
results were available. Those who were negative at baseline
for SARS-CoV-2 by RT-PCR (nasopharyngeal and nasal
swabs) and serology comprised the prevention population.
Participants positive at baseline for SARS-CoV-2 by RT-PCR
and negative for serology comprised a treatment population
for which results will be presented in more detail in a future
publication. The safety population included all participants
who received bamlanivimab or placebo regardless of base-
line serostatus.
Given the reported disparities in the prevalence of
COVID-19 across racial/ethnic subgroups,17 information on this
variable was collected by study personnel based on fixed cat-
egories selected by the study participants.
Randomization
Participants enrolled in the study from August 2 to November
20, 2020. Database lock was on January 13, 2021. Eligible
Key Points
Question Among residents and staff of skilled nursing and
assisted living facilities with high risk of SARS-CoV-2 exposure,
what is the effect of bamlanivimab on the incidence of COVID-19?
Findings This randomized phase 3 clinical trial included 966
participants who were residents and staff at US skilled nursing and
assisted living facilities with at least 1 confirmed SARS-CoV-2 index
case and who were negative at baseline for SARS-CoV-2 infection
and serology, enrolled from August to November 2020. The
incidence of COVID-19 infection among those treated with
bamlanivimab vs placebo was 8.5% vs 15.2%, respectively, a
difference that was statistically significant.
Meaning Bamlanivimab monotherapy compared with placebo
reduced the risk of COVID-19 in residents and staff of skilled
nursing and assisted living facilities.
Methods
Trial Design and Participants
This clinical trial is an ongoing, multipart, phase 3, random-
ized, double-blind, placebo-controlled, single-dose study 
evaluating the efficacy and safety of bamlanivimab in pre-
venting COVID-19 and SARS-CoV-2 infection.
The trial complied with the Declaration of Helsinki,16 the 
Council for International Organizations of Medical Sciences, 
the International Conference on Harmonization Guidelines for 
Good Clinical Practice, and applicable laws and regulations. 
The study was reviewed and approved by a centralized insti-
tutional review board (Advarra). Study participants or their le-
gal representatives provided written informed consent prior 
to treatment randomization.
The trial enrolled residents and staff at 74 skilled nursing 
and assisted living facilities in the United States (California, 
Colorado, Florida, Illinois, Indiana, Kentucky, Missouri,
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patients were randomized to receive 4200 mg of bamla-
nivimab or placebo. All participants were centrally random-
ized to study intervention using an interactive web response
system (IWRS). Before the study was initiated, the log-in
information and directions for the IWRS were provided to
each site. To achieve between-group comparability, block
randomization within each facility was used (block size of 4).
Randomized participants within the facility were stratified by
role within the facility (resident vs facility staff) and by sex.
Intervention
Participants received a single intravenous infusion of 4200 mg
of bamlanivimab or placebo. The evaluation period was 8 weeks,
with follow-up to 24 weeks. This article includes results from
the prevention population in part 1 of this multipart study (see
protocol and statistical analysis plan in Supplement 1).
Clinical and Laboratory Monitoring
Nasal swabs were obtained on study days 1, 8, 15, 22, 29, 36,
43, 50, and 57 and during postevaluation follow-up for detec-
tion of SARS-CoV-2 by RT-PCR. Serology samples were ob-
tained at baseline, study day 29, and study day 57 during the
8-week evaluation period. Participants completed a question-
naire at screening and daily during the evaluation period on
symptoms and signs associated with COVID-19 experienced
during the past 24 hours. Vital signs, hospitalization events,
clinical symptoms, and interventions of interest were re-
corded daily. Participants testing positive for SARS-CoV-2 were
treated per standard of care.
Outcomes
The primary outcome was cumulative incidence within 8
weeks of randomization of COVID-19, defined as detection of
SARS-CoV-2 by RT-PCR and presence of mild or worse disease
severity within 21 days of detection. Mild or worse disease
severity included mild, moderate, severe, and critical disease
severity and death due to COVID-19 (eTable 1 in Supple-
ment 2). Key secondary outcomes included cumulative inci-
dence within 8 weeks of randomization of moderate or worse
COVID-19 severity, defined as detection of SARS-CoV-2 by
RT-PCR and moderate or worse disease severity within 21
days of detection, and cumulative incidence within 4 weeks
of randomization of SARS-CoV-2 infection, defined as detec-
tion of SARS-CoV-2 by RT-PCR. Moderate or worse disease
severity included moderate, severe, and critical disease
severity and death due to COVID-19 (eTable 1). eTable 1 pro-
vides a list of symptoms and signs associated with mild,
moderate, severe, and critical COVID-19. There were 4 other
secondary end points, including mortality attributed to
COVID-19. Other secondary end points not reported herein
include incidence of SARS-CoV-2 infection 8 weeks after ran-
domization, frequency of hospitalization or death due to
COVID-19, and characterization of participant clinical status.
Exploratory end points included characterization of SARS-
CoV-2 viral end points in participants who became positive for
SARS-CoV-2 infection by RT-PCR (proportion of participants
who achieved SARS-CoV-2 clearance, defined as a single nega-
tive SARS-CoV-2 RT-PCR test result within 1, 2, or 3 weeks of
an initial positive SARS-CoV-2 RT-PCR test result; and time to
SARS-CoV-2 clearance). For a full list of secondary and explor-
atory outcomes, see the protocol in Supplement 1.
Sample Size Calculation
The trial was designed as event driven. Thirty-three events were
calculated to be necessary to show statistical superiority of
bamlanivimab, 4200 mg, over placebo in each of the primary
and key secondary end points using the formula for propor-
tional hazards models.18 The prespecified minimum detect-
able effect size was a relative risk of 0.33, which was chosen
based on what was considered medically meaningful by the
clinical experts on the author team. Assuming 90% power for
the primary and key secondary end points and an 8-week pla-
cebo-group event rate of 4% for moderate-severity or worse
COVID-19, a sample size of approximately 1300 participants
in the prevention population was expected to yield the needed
number of events for each end point.
Statistical Analysis
The National Institute of Allergy and Infectious Diseases data
and safety monitoring board (DSMB) monitored the safety and
efficacy of the trial monthly and conducted the review of an
interim analysis of the first 300 facility residents and a sub-
sequent analysis after all participants reached study day 57.
At primary database lock, the DSMB recommended that the
study should continue to obtain full outcome data for all par-
ticipants while maintaining blinding of all investigators,
participants, and study staff.
All randomized participants (regardless of whether they
received any doses of study treatment or if they received the
correct treatment) who were SARS-CoV-2 RT-PCR negative and
serology negative at baseline were included in the efficacy
analysis. Participants were analyzed according to the treat-
ment group to which they were randomized (see section 6.1.1
of the statistical analysis plan in Supplement 1).
For the primary and key secondary end points, logistic
regression was used to compare the treatments, with treat-
ment, facility, and the stratification factors of sex and role in
the facility (resident or staff) included as fixed effects. The
inclusion of facility in the model was important, as it
accounted for potentially highly heterogeneous extent of
outbreak and, hence, levels of exposure to SARS-CoV-2,
across facilities. Treatment effects were compared using
2-sided tests with an α = .05 unless otherwise stated. Two-
sided 95% Wald confidence intervals for odds ratios and
P values from a Rao test are presented. To control for multi-
plicity, a graphical testing sequence approach was prespeci-
fied to test the primary and key secondary end points. If the
primary end point of mild or worse COVID-19 was met at the
2-sided α = .05 significance level, the end points of moderate
or worse COVID-19 and SARS-CoV-2 infection were tested at
the α = .04 and α = .01 levels, respectively. If either of these
end points were met, the remaining end point was then
tested at the α = .05 level. All other analyses were conducted
at the 2-sided α = .05 significance level without adjustments
for multiplicity, and the results should be interpreted as
exploratory. Only confirmed SARS-CoV-2 infections and
chronic obstructive pulmonary disease, or other chronic
respiratory disease. Details regarding these methods are
provided in section 6 of the statistical analysis plan in
Supplement 1.
In the process of closing out the study, it was discovered
that for a subset of participants who required legally autho-
rized representatives for consent, more symptom data were
collected than permitted by the protocol. A sensitivity analy-
sis that excluded those symptom data was carried out.
The statistical analyses were performed using SAS ver-
sion 9.4 or higher (SAS Institute Inc), FACTS version 6.0 or




A total of 1297 participants enrolled in the study. Of the 1175
randomized participants who received study drug, 588 re-
ceived 4200 mg of bamlanivimab and 587 received placebo
(Figure 1); 966 participants comprised the prevention popu-
lation (negative at baseline for SARS-CoV-2 by RT-PCR and se-
rology), of which 300 were residents. A total of 132 partici-
pants comprised the treatment population (positive at baseline
for SARS-CoV-2 infection and negative for SARS-CoV-2 serol-
ogy at baseline) with either presymptomatic or asymptom-
atic infection. Data from the treatment population will be re-
ported in a future publication.
Baseline demographics and risk factors were balanced be-
tween the bamlanivimab group and the placebo group (Table 1;
eTables 2-4 in Supplement 2). Among participants in the pre-
vention population, the median age was 53.0 (range, 18-104)
years, 29.2% (282 of 966) were aged 65 years or older, and
74.7% (722 of 966) were female. Among the resident partici-
pants in the prevention population, the median age was 76.0
(range, 31-104) years, 78.3% (235 of 300) were aged 65 years
or older at the time of randomization, and 59.7% (179 of 300)
were female.
Participants in the prevention population who were at
high risk of severe COVID-19 comprised the high-risk pre-
vention population (described in eTable 1 in Supplement 2).
All 300 resident participants and 41.3% (275 of 666) of
the staff participants were included in the high-risk preven-
tion population.
Primary Outcome
For the overall prevention population, 114 participants
(11.9%) experienced mild or worse COVID-19 by day 57; par-
ticipants who received bamlanivimab had significantly
reduced incidence of mild or worse COVID-19 compared with
participants who received placebo (8.5% vs 15.2%; odds ratio,
0.43; 95% CI, 0.28-0.68; P < .001), with an absolute risk dif-
ference of −6.6 (95% CI, −10.7 to −2.6) percentage points
(eFigure 1 in Supplement 2). In the resident prevention popu-
lation, incidence of mild or worse COVID-19 was significantly
lower in the bamlanivimab group compared with the placebo
group (8.8% vs 22.5%; odds ratio, 0.20; 95% CI, 0.08-0.49;
Figure 1. Flow of Participants Through the BLAZE-2 Randomized
Clinical Trial









588 Randomized to receive
bamlanivimab, 4200 mg
571 Completed infusion
17 Did not complete infusion
587 Randomized to receive placebo
582 Completed infusion
5 Did not complete infusion
484 Included in primary analysis
104 Excluded (SARS-CoV-2 RT-PCR
or serology positive at baseline)
482 Included in primary analysis
105 Excluded (SARS-CoV-2 RT-PCR
or serology positive at baseline)
38 Were SARS-CoV-2 serology
positive at baseline
550 Were SARS-CoV-2 serology
negative at baseline
484 Were SARS-CoV-2 RT-PCR
negative at baseline
(prevention population)
66 Were SARS-CoV-2 RT-PCR
positive at baseline
(treatment population)c
39 Were SARS-CoV-2 serology
positive at baseline
548 Were SARS-CoV-2 serology
negative at baseline
482 Were SARS-CoV-2 RT-PCR
negative at baseline
(prevention population)
66 Were SARS-CoV-2 RT-PCR
positive at baseline
(treatment population)c
RT-PCR indicates reverse transcriptase–polymerase chain reaction.
a A majority of the 95 screening failures were due to a lack of venous access
sufficient to allow intravenous infusions and blood sampling per protocol
(45 participants) or due to a serious concomitant systemic disease, condition,
or disorder that in the opinion of investigators should preclude participation
(34 participants), as described in sections 5.1 and 5.2 of the trial protocol
(Supplement 1).
b One participant provided signed consent but did not return for infusion, and
for 1 participant, infusion nurses were unable to secure intravenous access
despite multiple attempts.
c The treatment population will be reported on in a future publication.
COVID-19 cases were included in the analysis. If a participant 
discontinued prior to a confirmed event for a given end 
point, he or she did not contribute any event in the logistic 
regression and was censored at the time of discontinuation in 
the time-to-event analysis. Less than 4% of participants dis-
continued  within  the  end-point  windows.  For  other  
approaches to handling of missing data, see sections 6.3.1 
and 6.3.2 of the statistical analysis plan in Supplement 1.
Exploratory subgroup analyses of primary and key sec-
ondary end points within the resident (prespecified) and 
high-risk (post hoc) populations were also conducted. High-
risk participants included all residents of the skilled nursing 
or assisted living facilities and staff who satisfied at least 1 
of the following at the time of screening: aged 65 years or 
older with a body mass index of 35 or higher, chronic kidney 
disease, type 1 or type 2 diabetes, or immunosuppressive 
disease or receiving immunosuppressive treatment; or aged 
55 years or older with cardiovascular disease, hypertension,
(Reprinted)
P < .001), for an absolute risk difference of −13.7 (95% CI,
−21.9 to −5.4) percentage points (Figure 2). Among the staff
in the prevention population, incidence of mild or worse
COVID-19 was not significantly different in the bamlanivimab
group compared with the placebo group (8.4% vs 12.2%;
odds ratio, 0.58; 95% CI, 0.33-1.02; P = .06), with an absolute
risk difference of −3.8 (95% CI, −8.4 to 0.8) percentage points
(P = .12 for interaction) (Figure 2). In the high-risk prevention
population, a post hoc analysis showed that the incidence of
mild or worse COVID-19 was also lower in the bamlanivimab
group compared with the placebo group (eFigure 1).
Key Secondary Outcomes
Two key secondary end points were assessed within the mul-
tiplicity-controlled serial gatekeeping testing scheme: the in-
cidence of moderate or worse severity COVID-19 by day 57 and
the incidence of SARS-CoV-2 infection by day 29. In the over-
all prevention population, administration of bamlanivimab





































































































































Participants were negative at baseline for SARS-CoV-2 by reverse transcriptase–polymerase chain reaction and serology. More than 95% of participants were
followed up beyond day 57. Similar data for other subgroups are shown in eFigure 1 in Supplement 2.












Median (range), y 76.0 (31-104) 75.0 (41-96) 43.0 (18-82) 42.0 (18-74)
No. (%) ≥65 y 126 (78.3) 109 (78.4) 19 (5.9) 28 (8.2)
Sex, No. (%)
Female 95 (59.0) 84 (60.4) 260 (80.5) 283 (82.5)
Male 66 (41.0) 55 (39.6) 63 (19.5) 60 (17.5)
Race, No./total (%)b
White 145/160 (90.6) 126/138 (91.3) 284/322 (88.2) 303/340 (89.1)
Black or African American 13/160 (8.1) 11/138 (8.0) 25/322 (7.8) 30/340 (8.8)
American Indian
or Alaska Native
0 0 4/322 (1.2) 1/340 (0.3)
Asian 1/160 (0.6) 0 5/322 (1.6) 5/340 (1.5)
Native Hawaiian
or other Pacific Islander
1/160 (0.6) 0 1/322 (0.3) 1/340 (0.3)
Multiple 0 1/138 (0.7) 3/322 (0.9) 0
Hispanic or Latino ethnicity,
No./total (%)b
3/160 (1.9) 7/139 (5.0) 17/323 (5.3) 21/343 (6.1)




29.9 (16.4-62.0) 30.3 (16.5-65.7)
At high risk of severe COVID-19,
No. (%)d
161 (100) 139 (100) 132 (40.9) 143 (41.7)
a Participants were negative at
baseline for SARS-CoV-2 by reverse
transcriptase–polymerase chain
reaction and serology.
b Race and ethnicity were
self-reported by participants.
c Body mass index is calculated as
weight in kilograms divided by the
square of height in meters.
d All residents were high risk by
definition. Staff were high risk if
they met 1 or more of the following
at the time of screening: (1) aged
65 years with body mass index
35, chronic kidney disease, type 1
or type 2 diabetes,
immunosuppressive disease, or
receiving immunosuppressive
treatment or (2) aged 55 years
with cardiovascular disease,
hypertension, chronic obstructive
pulmonary disease, or other chronic
respiratory disease.
Exploratory End Points
A total of 282 participants (29.3%) in the prevention popula-
tion tested positive for SARS-CoV-2 by RT-PCR within 8 weeks
of randomization. Participants who received bamlanivimab had
lower viral loads (converted from cycle threshold values; see
Section 6 of the statistical analysis plan in Supplement 1) com-
pared with placebo recipients at the time of their first posi-
tive test result (2.44 vs 3.64 log10 viral load) and the decrease
in mean viral load at first positive RT-PCR status to mean vi-
ral load at week 1 was greater in the bamlanivimab group com-
pared with the placebo group (−0.8 [95% CI, −1.22 to −0.39]
log10 viral load; P < .001) (Figure 3, C-E). The proportion of par-
ticipants who achieved viral clearance after testing positive for
SARS-CoV-2 was greater in the bamlanivimab group com-
pared with the placebo group at 1 week (14.9% vs 8.3%), 2 weeks
(86.0% vs 61.3%), and 3 weeks (93.0% vs 78.0%) (eFigure 3 in
Supplement 2).
Post Hoc Analyses
In a post hoc analysis of the participants in the prevention
population who became infected with SARS-CoV-2 (tested posi-
tive by RT-PCR prior to day 57), fewer participants were SARS-
CoV-2 serology positive in the bamlanivimab group com-
pared with the placebo group by study day 57 (2.6% vs 15.0%)
(eFigure 4 in Supplement 2).
Sensitivity Analysis
In the sensitivity analysis, some symptom data were ex-
cluded for 128 residents. For the primary end point, the num-
ber of events was reduced by 4, with 3 fewer events in the bam-
lanivimab group and 1 fewer event in the placebo group
(eTables 7-8 in Supplement 2). The results remained statisti-
cally significant, with a similar effect size.
Adverse Events
Of the 1175 participants included in the overall safety popula-
tion, serious adverse events were reported in 3.7% of bamla-
nivimab recipients and 3.2% of placebo recipients (Table 2).
The number of deaths not attributed to COVID-19 were 5 (0.9%)
and 6 (1.0%) in the bamlanivimab and placebo groups, respec-
tively. Adverse events were reported in 20.1% of the bamla-
nivimab group and 18.9% of the placebo group. Percentages
of mild, moderate, and severe adverse events were balanced
between both groups. Rates of adverse events occurring in 1%
or more of the safety population were generally balanced across
both treatment groups (Table 2; eTable 6 in Supplement 2).
Hypersensitivity reactions within 24 hours of dose admin-
istration were reported in 3 participants (0.5%) in the bamla-
nivimab group and none in the placebo group. The percent-
age of participants who received a complete infusion of
randomized treatment was 97.1% for bamlanivimab and 99.1%
for placebo.
Discussion
This phase 3 clinical trial conducted in skilled nursing and as-
sisted living facilities demonstrated that bamlanivimab was
significantly reduced the incidence of moderate or worse 
COVID-19 compared with placebo (8.3% vs 14.1%; odds ratio, 
0.46; 95% CI, 0.29-0.73; P < .001), with an absolute risk dif-
ference of −5.8 (95% CI, −9.8 to −1.8) percentage points (eFig-
ure 2A in  Supplement 2). In the resident prevention popula-
tion, incidence of moderate or worse COVID-19 was also lower 
among bamlanivimab recipients compared with placebo re-
cipients (8.8% vs 21.7%; odds ratio, 0.20; 95% CI, 0.08-0.49), 
with an absolute risk difference of −12.9 (95% CI, −21.1 to −4.8) 
percentage points (eFigure 2A). Among the staff in the pre-
vention population, 8.1% of staff participants in the bamla-
nivimab group and 11.1% of staff participants in the placebo 
group experienced moderate or worse COVID-19 by day 57 
(odds ratio, 0.61; 95% CI, 0.34-1.09), with an absolute risk dif-
ference of −3.0 (95% CI, −7.4 to 1.5) percentage points (P = .11  
for interaction) (eFigure 2A). In the high-risk prevention popu-
lation, a post hoc analysis showed that fewer cases of moder-
ate or worse COVID-19 occurred in participants who received 
bamlanivimab compared with those who received placebo 
(eFigure 2A).
Assessment of infection with SARS-CoV-2 by RT-PCR within 
4 weeks of randomization revealed that 198 participants (20.6%) 
in the prevention population tested positive for SARS-CoV-2. 
Bamlanivimab was associated with significantly lower inci-
dence of SARS-CoV-2 infection compared with placebo (17.9%
vs 23.3%; odds ratio, 0.66; 95% CI, 0.46-0.94; P = .02), with an 
absolute risk difference of −5.4 (95% CI, −10.5 to −0.3) percent-
age points (eFigure 2B in Supplement 2). Bamlanivimab was also 
associated with lower incidence of SARS-CoV-2 infection by 
week 4 in the resident and high-risk prevention populations. In 
the resident prevention population, 15.1% (24 of 159) of resi-
dent participants who received bamlanivimab and 31.9% (44 of 
138) of residents who received placebo tested positive for SARS-
CoV-2 by RT-PCR (odds ratio, 0.24; 95% CI, 0.12-0.51]), with an 
absolute risk difference of −16.8 (95% CI, −26.4 to −7.2) per-
centage points (Figure 3A). Among the staff in the prevention 
population, 19.3% of staff participants in the bamlanivimab 
group and 19.8% in the placebo group tested positive for SARS-
CoV-2 by RT-PCR by week 4 (odds ratio, 0.96; 95% CI, 0.62-
1.49), with an absolute risk difference of −0.5 (95% CI, −6.5 to 
5.5) percentage points (P = .005 for interaction) (Figure 3B). In 
the high-risk prevention population, a post hoc analysis showed 
that fewer participants in the bamlanivimab group tested posi-
tive for SARS-CoV-2 by RT-PCR compared with the placebo group 
(eFigure 2B).
Other Secondary Outcomes
An additional prespecified secondary end point of this study 
was mortality due to COVID-19. All 5 COVID-19–related deaths 
in the study occurred in resident participants randomized to 
receive placebo. By day 57, in the prevention population, 4 
COVID-19-related deaths occurred among participants in the 
placebo group (n = 482) vs 0 in the bamlanivimab group 
(n = 484) (eTable 5 in Supplement 2). In the treatment popu-
lation (see Methods section), 1 COVID-19–related death oc-
curred among resident participants in the placebo group 
(n = 66) vs 0 in the bamlanivimab group (n = 66). Deaths oc-
curred in residents ranging in age from 65 to 89 years.
printed)
Figure 3. Time From Infusion to Detection of SARS-CoV-2 by RT-PCR With Bamlanivimab vs Placebo and Viral Load in Participants Who Tested Positive
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A and B, Kaplan-Meier curves for time from infusion to detection of SARS-CoV-2 by
reverse transcriptase–polymerase chain reaction (RT-PCR) with bamlanivimab vs
placebo among resident and staff participants. Participants were negative at
baseline for SARS-CoV-2 by RT-PCR and serology. More than 95% of participants
were followed up beyond day 57. Similar data for other subgroups are shown in
eFigure 2B in Supplement 2. C and D, Spaghetti plots for log10 viral load over time
for resident and staff participants. Participants were negative at baseline for
SARS-CoV-2 by RT-PCR and serology. Participants with at least 1 positive
postbaseline SARS-CoV-2 RT-PCR test result: bamlanivimab group, n = 23 residents
and n = 62 staff; placebo group, n = 44 residents and n = 68 staff. Time 0 represents
the time of a participant’s first positive RT-PCR test result. Each line represents
a participant. E, Box plot for log10 viral load over time for participants with at least 1
positive postbaseline SARS-CoV-2 RT-PCR test result. Time 0 represents the time
of a participant’s first positive RT-PCR test result. Box tops and bottoms indicate
interquartile ranges; solid horizontal bars, medians; hollow squares, means; whiskers,
lowest and highest observations within 1.5 interquartile ranges of the first and third
quartiles; and dots, outliers. In the later weeks, the 25th, 50th, and 75th percentiles
are coincident, so the boxes appear as solid horizontal bars.
through prophylaxis could potentially slow further spread of
disease, although this has yet to be tested.
All COVID-19–related deaths reported during this trial oc-
curred among participants in the placebo group. This poten-
tial protective effect of bamlanivimab in reducing mortality
could be due to fewer participants acquiring SARS-CoV-2 in-
fections, as well as lower viral loads among those infected, since
persistently high viral load has previously been identified as
a risk factor for worse outcomes.15
In contrast to the resident and high-risk prevention popu-
lations, there was no significant difference in incidence of
COVID-19 or SARS-CoV-2 infection in low-risk staff partici-
pants who received bamlanivimab compared with placebo. In-
terpretation of this observation yields various hypotheses given
that staff (vs residents) could have differential exposures to in-
fected persons (in the facility and in the community); how-
ever, these findings are consistent with the hypothesis that ad-
ministration of neutralizing monoclonal antibodies has
maximal effect in older people and in those at high risk of se-
vere disease whose immune response to SARS-CoV-2 infec-
tion may be suboptimal.11 Additionally, the endogenous im-
mune response in the majority of individuals infected with
SARS-CoV-2 can effectively fight infection,20 supporting the
findings from this study that show no benefit of bamla-
nivimab over placebo among the entire staff population.
Among those in the prevention population who tested posi-
tive for SARS-CoV-2 infection by RT-PCR by day 57, serocon-
version was less frequent among participants who received
bamlanivimab compared with placebo, possibly due to faster
viral clearance and decreased antigenic exposure. It has been
reported that some people with asymptomatic infection and
limited inflammatory response may not demonstrate sero-
conversion as evidence of COVID-19 infection.21
The Emergency Use Authorization for bamlanivimab as
monotherapy was revoked by the US Food and Drug Admin-
istration (FDA). It noted that “based on…the sustained in-
crease of SARS-CoV-2 viral variants that are resistant to bam-
lanivimab alone resulting in the increased risk for treatment
failure, the FDA has determined that the known and poten-
tial benefits of bamlanivimab, when administered alone, no
longer outweigh the known and potential risks for its autho-
rized use.”22 However, authorization of bamlanivimab in com-
bination with etesevimab remains in place. The BLAZE-2 study
started before such variants were spreading in the United
States. As such, the results presented herein primarily repre-
sent validation of the use of neutralizing monoclonal antibod-
ies as protective passive immunotherapy against COVID-19,
with potential clinical relevance for antibody therapies in con-
tinued distribution.
Limitations
This study has several limitations. First, the study was con-
ducted prior to widespread vaccine rollout, and any partici-
pant vaccinated against SARS-CoV-2 prior to screening was
excluded. Studies are necessary to determine whether neu-
tralizing monoclonal antibodies affect vaccine performance
in this population. Second, while both nasopharyngeal and
nasal swabs were obtained for detection of SARS-CoV-2







Participants with ≥1 treatment-emergent
adverse eventb
118 (20.1) 111 (18.9)
Severity of treatment-emergent
adverse eventb,c
Severe 19 (3.2) 17 (2.9)
Moderate 29 (4.9) 31 (5.3)
Mild 66 (11.2) 61 (10.4)
Most common treatment-emergent
adverse events (occurring in ≥1%
of bamlanivimab or placebo recipients)d
Urinary tract infection 12 (2.0) 14 (2.4)
Hypertension 7 (1.2) 10 (1.7)
Fall 2 (0.3) 6 (1.0)
Dizziness 4 (0.7) 6 (1.0)
Arthralgia 6 (1.0) 4 (0.7)
Serious adverse eventse 22 (3.7) 19 (3.2)
Deaths resulting from adverse eventf 5 (0.9) 6 (1.0)
Discontinuation from study participation
due to adverse event (including death)
5 (0.9) 6 (1.0)
a Includes full randomized population that received at least 1 infusion.
Study-specific clinical events related to COVID-19 were reported separately
and not as adverse events (per protocol).
b A treatment-emergent adverse event was defined as an event that first
occurred or worsened in severity after baseline.
c Patients with multiple occurrences of these categories were counted once for
each category. Patients may be counted in more than 1 category.
d The preferred terms were defined according to the Medical Dictionary for
Regulatory Activities, version 23.0.
e The serious adverse events in the placebo group were pneumonia,
bacteremia, sepsis, septic shock, upper respiratory tract infection, urinary
tract infection (bacterial), cardiac failure (congestive), cardiorespiratory arrest,
cerebrovascular accident, dementia, syncope, femur fracture, corneal injury,
open-globe injury, abdominal distension, ascites, mouth hemorrhage,
increased blood creatinine, hyperkalemia, chronic kidney disease,
ureterolithiasis, chronic obstructive pulmonary disease, epistaxis, thyrotoxic
crisis, and hypovolemic shock. The serious adverse events in the
bamlanivimab group were urinary tract infection (n = 4), atrial fibrillation
(n = 2), pneumonia, AIDS, gastroenteritis, groin abscess, cardiac failure
(congestive), cardiorespiratory arrest, acute myocardial infarction, coronary
artery disease, cerebrovascular accident, headache, hypoesthesia,
paresthesia, transient ischemic attack, vascular dementia, road traffic incident,
spinal compression fracture, anemia, iron-deficiency anemia,
thrombocytopenia, small intestinal obstruction, increased ammonia level,
hypoglycemia, bile duct stone, lumbar spinal stenosis, and psychotic disorder.
f Five deaths reported in the bamlanivimab group were due to cardiorespiratory
arrest, AIDS, acute myocardial infarction, pneumonia, and vascular dementia.
Six deaths reported in the placebo group were due to cardiorespiratory arrest,
cardiac failure (congestive), chronic obstructive pulmonary disease, dementia,
hypovolemic shock, and upper respiratory tract infection.
effective in reducing the incidence of mild or worse COVID-19 
in residents and participants at high risk of severe COVID-19. 
Bamlanivimab was also associated with lower rates of 
infection in residents and high-risk individuals. Participants 
in the prevention population who received bamlanivimab and 
acquired SARS-CoV-2 had lower baseline viral loads and shorter 
time to viral clearance compared with participants who re-
ceived placebo. Since higher viral loads may correlate with 
higher degrees of infectiousness,19 decreasing viral load
Reprinted)
infection prior to dose administration, nasal swabs alone
were obtained for subsequent SARS-CoV-2 detection during
the evaluation and follow-up period. Use of nasal swabs for
detection of SARS-CoV-2 may have lower sensitivity than
nasopharyngeal swabs.23
Third, a variety of SARS-CoV-2 variants have recently been
identified outside of this study,24-26 some of which have re-
duced susceptibility to vaccine-induced protection and to neu-
tralization by convalescent serum and several monoclonal
antibodies.27 Such variants represent a challenge in the selec-
tion of agents for prevention and treatment of SARS-CoV-2 and
have already triggered use of combinations of monoclonal
antibodies15,20 and discovery of novel therapeutic antibodies.
Fourth, there was very little racial diversity in the partici-
pant population. This was a reflection of the populations in fa-
cilities who agreed to participate in the trial.
Conclusions
Among residents and staff in skilled nursing and assisted liv-
ing facilities, treatment during August-November 2020 with
bamlanivimab monotherapy reduced the incidence of
COVID-19 infection. Further research is needed to assess pre-
ventive efficacy with current patterns of viral strains with avail-
able combination monoclonal antibody therapy.
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